HEMO.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:25):

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases...

Stats
Dzisiejszy wolumen	1.89M
Średni wolumen	16.31M
Kapitalizacja rynkowa	21.27M
EPS	£0 ( 2024-04-25 )
Następna data zysków	( £0 ) 2024-06-28
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.650
ATR14	£0.0240 (1.45%)

Wolumen Korelacja

Długi: -0.19 (neutral)

Krótki: -0.75 (moderate negative)

Signal:(52.56) Neutral

Hemogenyx Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hemogenyx Pharmaceuticals Korelacja - Waluta/Towar

-0.25
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.42
( neutral )

Hemogenyx Pharmaceuticals Finanse

Annual	2023
Przychody:	£0
Zysk brutto:	£-645 681 (0.00 %)
EPS:	£-0.00600

FY	2023
Przychody:	£0
Zysk brutto:	£-645 681 (0.00 %)
EPS:	£-0.00600

FY	2022
Przychody:	£0
Zysk brutto:	£-2.60M (0.00 %)
EPS:	£-0.00440

FY	2021
Przychody:	£0.00
Zysk brutto:	£-321 230 (0.00 %)
EPS:	£-0.0123

Financial Reports:

No articles found.

Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.